EMA Recommends Extension of Therapeutic Indications for Retifanlimab By Ogkologos - February 6, 2026 443 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of adult patients with squamous cell carcinoma of the anal canal Source RELATED ARTICLESMORE FROM AUTHOR Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Relacorilant Annual Multicancer Early Detection Test Not Associated with a Lower Incidence Rate of Stage III or IV Cancer After Three Screening Rounds and 12... MOST POPULAR Breast Cancer Survivors in Happy Romantic Relationships Are Healthier, Study Says June 5, 2020 Cancer in children and young people: how far we’ve come September 29, 2021 Pirtobrutinib Shows Efficacy in Patients with Heavily Pretreated CLL or SLL... July 18, 2023 PET-2-Guided BrECADD Better Tolerated and More Effective than eBEACOPP in Patients... July 16, 2024 Load more HOT NEWS Neoadjuvant Atezolizumab Plus Chemotherapy Is Safe and Has Promising Activity in... ΙΣΤΟΡΙΑ Working to Raise Prostate Cancer Awareness: A Patient Advocate’s Story Investigating suspected prostate cancer: improving GP-patient communication
